PT-141 (Bremelanotide) Compounding Legal Status

FDA Approval History for Bremelanotide

The FDA approved bremelanotide on June 21, 2019, under NDA 210557, making it the first melanocortin receptor agonist cleared for a sexual health indication in women. Approval was based primarily on the two RECONNECT phase III trials, which enrolled a combined 1,247 premenopausal women with generalized acquired HSDD [1].

The RECONNECT Trials

In the RECONNECT studies, women self-administered bremelanotide 1.75 mg subcutaneously on an as-needed basis for 24 weeks. The co-primary endpoints were change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score and the Female Sexual Function Index (FSFI) desire domain score. Bremelanotide produced a statistically significant improvement over placebo on both measures (P<0.001 for FSDS-DAO Item 13 in both trials) [1]. The treatment effect on desire, while statistically significant, was modest in absolute magnitude, a point the FDA's review team noted in its approval package [2].

Regulatory Review Timeline

Palatin Technologies submitted the NDA in March 2018. The FDA initially set a Prescription Drug User Fee Act (PDUFA) date of January 2019 but extended review by three months for additional analysis. No advisory committee meeting was convened. AMAG Pharmaceuticals held U.S. Commercial rights at approval, though those rights have changed hands in subsequent corporate transactions [2].

Comparison to Flibanserin

Bremelanotide's approval arrived four years after flibanserin (Addyi), the only other FDA-approved drug for premenopausal HSDD. The two drugs differ in mechanism, route, and dosing. Flibanserin is a daily oral 5-HT1A agonist/5-HT2A antagonist carrying an alcohol interaction boxed warning and a REMS program. Bremelanotide carries neither a boxed warning nor a REMS, though the label includes specific precautions regarding cardiovascular effects and nausea [3].

What the Bremelanotide (Vyleesi) Label Says

The Vyleesi prescribing information describes a focused indication, a narrow dosing window, and specific safety precautions that shape how clinicians use the drug and how compounders interpret regulatory boundaries.

Indication and Dosing

The label limits use to premenopausal women with acquired, generalized HSDD not explained by a co-existing medical or psychiatric condition, relationship problems, or medication effects. Each dose is 1.75 mg injected subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity. The label caps use at one injection per 24 hours and no more than 8 injections per calendar month [3].

Cardiovascular Precautions

Bremelanotide causes transient increases in systolic and diastolic blood pressure. In clinical trials, mean peak increases of approximately 6 mmHg systolic and 3 mmHg diastolic occurred roughly 2 to 3 hours post-dose, returning to baseline within 12 hours. The label advises against use in patients with uncontrolled hypertension or known cardiovascular disease and states the drug should not be used in patients taking antihypertensive medications without careful consideration of the blood pressure effect [3].

Nausea and Hyperpigmentation

Nausea was the most common adverse reaction in the RECONNECT trials, reported by approximately 40% of bremelanotide-treated women compared with 1% on placebo. It was the leading cause of discontinuation, accounting for 7.5% of treated women who stopped the drug. The label also warns of focal skin hyperpigmentation, particularly on the face, gingiva, and breasts, which may not resolve after discontinuation [1][3].

Compounding Rules: 503A vs. 503B

The legal pathway for compounding bremelanotide depends on the type of pharmacy, the commercial availability of the FDA-approved product, and state-level regulations. Two sections of the Federal Food, Drug, and Cosmetic Act govern most compounding: Section 503A (traditional compounding pharmacies) and Section 503B (outsourcing facilities).

Section 503A Compounding

Under Section 503A, a licensed pharmacist may compound a drug product for an individual patient based on a valid prescription from a licensed prescriber. The compounded product must differ meaningfully from the commercially available version (different strength, dosage form, or added ingredient for a patient-specific need) or the prescriber must determine that the commercially available product is not appropriate for the patient [4].

For bremelanotide, this means a 503A pharmacy could, in principle, prepare a patient-specific formulation if the prescribing clinician documents a clinical reason the commercial Vyleesi product does not meet the patient's needs. Adjusted concentrations, preservative-free formulations, or alternative injection volumes are examples of modifications that may qualify. The compound cannot be an "essentially a copy" of the commercial product dispensed without patient-specific justification [4].

Section 503B Outsourcing Facilities

Section 503B outsourcing facilities may compound without patient-specific prescriptions and distribute on a wholesale basis, but they face a stricter rule: they generally cannot compound drugs that are "essentially a copy" of a commercially available drug unless that drug appears on the FDA's drug shortage list. Bremelanotide is not currently listed on the FDA Drug Shortage Database, and Vyleesi remains commercially available [5].

This means most 503B outsourcing facilities cannot legally produce bremelanotide for distribution. The FDA has issued warning letters to compounders producing copies of commercially available drugs, and enforcement activity in this area has increased since 2020 [5].

State-Level Variations

State pharmacy boards add a layer of complexity. Some states restrict compounding of any FDA-approved product regardless of federal exemptions. Others permit it with additional documentation requirements. Texas, for example, requires the prescriber to include a statement on the prescription explaining why the commercial product is unsuitable. California's Board of Pharmacy has issued guidance specifying that compounders must maintain records demonstrating the clinical need for each compounded prescription [6].

The practical result: a bremelanotide compound legally dispensed in one state may not be legal in another, even from the same pharmacy chain.

Why PT-141 Compounding Is Common Despite the Rules

Despite the regulatory constraints, compounded bremelanotide circulates widely in telehealth and peptide clinic settings. Several factors drive this pattern.

Cost Differential

Vyleesi carries a wholesale acquisition cost (WAC) that has fluctuated significantly since launch. At its peak, a single-dose autoinjector was priced above $900. Insurance coverage has been inconsistent. Many commercial payers classify HSDD treatments as lifestyle drugs and exclude them from formularies. The result is high out-of-pocket cost for patients who want the branded product [7].

Compounded bremelanotide, by contrast, is often available at $30 to $80 per dose through compounding pharmacies, a price point that is 10- to 30-fold lower than the branded product. This price gap creates strong patient demand.

Off-Label Use in Men

The FDA approved bremelanotide only for premenopausal women with HSDD. No approved indication exists for men. Research on bremelanotide for male erectile dysfunction dates to early phase II trials, including a 2005 study of intranasal bremelanotide in men with erectile dysfunction that showed dose-dependent erectile responses [8]. The intranasal formulation was never approved due to blood pressure concerns flagged during development.

Compounding pharmacies have filled the gap by preparing injectable bremelanotide for off-label use in men. Because no FDA-approved bremelanotide product exists for men, the "essentially a copy" restriction is less clearly applicable, and some compounders and legal scholars argue that 503A compounding for male patients falls outside the scope of the commercial product's approved indication entirely.

This is a contested legal position. The FDA has not issued formal guidance specifically addressing indication-based distinctions in the "essentially a copy" analysis. Prescribers who order compounded bremelanotide for male patients should document the clinical rationale and understand that enforcement risk, while currently low, is not zero.

Telehealth Expansion

The growth of telehealth platforms prescribing peptides, including bremelanotide, accelerated during and after the COVID-19 public health emergency. Some platforms pair an online consultation with a compounding pharmacy fulfillment model. The FDA has signaled increased scrutiny of telehealth-to-compounding pipelines, particularly for drugs with approved commercial equivalents [9].

FDA Enforcement and the Broader Peptide Field

Bremelanotide exists within a broader FDA enforcement context that affects many compounded peptides used in hormone therapy, weight management, and sexual health.

The 2023-2025 Peptide Enforcement Wave

Between 2023 and 2025, the FDA issued multiple warning letters and import alerts targeting compounders and importers of peptides including BPC-157, thymosin alpha-1, and various growth hormone secretagogues. In November 2023, the FDA published a list of substances that have been nominated for inclusion on the "difficult to compound" list under Section 503B [10].

Bremelanotide has not appeared on the "difficult to compound" list or been the subject of a specific FDA enforcement action against compounders as of May 2026. Its status differs from bulk peptides like BPC-157 that lack any FDA-approved finished product: bremelanotide has a clear regulatory pathway through the approved Vyleesi product.

The Semaglutide Precedent

The FDA's approach to compounded semaglutide offers a relevant precedent. When semaglutide appeared on the drug shortage list, 503B outsourcing facilities could legally compound it. When the shortage resolved, the FDA moved to restrict compounding, prompting litigation and congressional attention. The outcome of semaglutide compounding disputes may shape enforcement policy for other commercially available drugs, including bremelanotide [11].

Post-Market Safety Data

Bremelanotide's post-market safety profile has remained broadly consistent with the clinical trial data, with a few areas of ongoing monitoring.

Cardiovascular Events

The FDA Adverse Event Reporting System (FAERS) database contains reports of hypertensive episodes and, rarely, syncope associated with bremelanotide use. No signal of myocardial infarction or stroke has emerged in post-market data through 2025, but the labeled precaution regarding cardiovascular disease remains active. The European Medicines Agency (EMA) has not approved bremelanotide; it remains a U.S.-only approved product [12].

Nausea Persistence

Post-market experience confirms that nausea remains the dominant tolerability barrier. Some clinicians have adopted dose-reduction strategies (compounded doses of 1.0 mg or 1.25 mg) to manage nausea while preserving efficacy. These dose modifications are off-label relative to the approved 1.75 mg dose and are one of the clinical rationales cited to support patient-specific 503A compounding [12].

Hyperpigmentation Reports

FAERS reports include cases of persistent facial hyperpigmentation extending beyond 6 months after drug discontinuation. The melanocortin-1 receptor mechanism makes this biologically plausible: bremelanotide stimulates melanogenesis through the same receptor pathway targeted by melanotan peptides. Patients with darker baseline skin tones may be at higher risk, though the clinical trial populations were predominantly white and data in diverse populations remain limited [1][3].

How Prescribers Should Approach Bremelanotide Today

Clinicians considering bremelanotide for a patient face a decision tree shaped by indication, cost, and regulatory environment.

For Premenopausal Women with HSDD

The most straightforward path is prescribing Vyleesi. If cost is prohibitive and insurance does not cover the branded product, a 503A compounding pharmacy may prepare patient-specific bremelanotide with documentation of the cost barrier or a clinically necessary modification (dose adjustment, preservative-free formulation). The prescriber should include a statement of medical necessity on the prescription [4].

For Off-Label Uses

No FDA-approved bremelanotide product exists for men, postmenopausal women, or indications beyond HSDD. Prescribers using bremelanotide off-label should document the evidence supporting their clinical decision, obtain informed consent noting the off-label status, and select a compounding pharmacy registered under 503A with appropriate quality controls [6].

Monitoring Recommendations

Regardless of source, prescribers should check baseline blood pressure before initiating bremelanotide, repeat blood pressure measurement 2 to 3 hours after the first dose, counsel patients on the 8-dose monthly ceiling, and examine skin at follow-up visits for hyperpigmentation, particularly on the face and breast tissue [3].

Patients with resting systolic blood pressure above 140 mmHg or diastolic above 90 mmHg should not receive bremelanotide until blood pressure is controlled.